MX337059B - Metodos y composiciones para modular la hemostasia. - Google Patents

Metodos y composiciones para modular la hemostasia.

Info

Publication number
MX337059B
MX337059B MX2012006837A MX2012006837A MX337059B MX 337059 B MX337059 B MX 337059B MX 2012006837 A MX2012006837 A MX 2012006837A MX 2012006837 A MX2012006837 A MX 2012006837A MX 337059 B MX337059 B MX 337059B
Authority
MX
Mexico
Prior art keywords
methods
hemostasia
modulate
compositions
variants
Prior art date
Application number
MX2012006837A
Other languages
English (en)
Inventor
Rodney M Camire
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of MX337059B publication Critical patent/MX337059B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una variante del Factor Xa que modula la hemostasis que comprende al menos una mutación por substitución den los aminoácidos 41-179 y 235-488 de SEQ ID NO: 1, en donde la Val en la posición 236 se sustituye con un aminoácido en la posición 235 no es Val o Ala.
MX2012006837A 2005-11-15 2008-05-15 Metodos y composiciones para modular la hemostasia. MX337059B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15

Publications (1)

Publication Number Publication Date
MX337059B true MX337059B (es) 2016-02-09

Family

ID=38049397

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012006836A MX336958B (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2008006313A MX2008006313A (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2012006837A MX337059B (es) 2005-11-15 2008-05-15 Metodos y composiciones para modular la hemostasia.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2012006836A MX336958B (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.
MX2008006313A MX2008006313A (es) 2005-11-15 2006-03-21 Metodos y composiciones para modular la hemostasia.

Country Status (25)

Country Link
US (4) US8383386B2 (es)
EP (4) EP1948690B1 (es)
JP (4) JP5823088B2 (es)
KR (4) KR101600158B1 (es)
CN (1) CN101356192B (es)
AU (1) AU2006315175B2 (es)
BR (1) BRPI0618654B1 (es)
CA (2) CA2629491C (es)
CR (1) CR9956A (es)
DK (1) DK1948690T3 (es)
EC (1) ECSP088452A (es)
ES (2) ES2549929T3 (es)
GT (1) GT200800065A (es)
IL (1) IL191310A (es)
MX (3) MX336958B (es)
MY (1) MY162181A (es)
NO (3) NO345177B1 (es)
NZ (1) NZ568108A (es)
PL (1) PL1948690T3 (es)
PT (1) PT1948690E (es)
RU (2) RU2008123398A (es)
SI (1) SI1948690T1 (es)
SV (1) SV2008002906A (es)
WO (1) WO2007059513A2 (es)
ZA (1) ZA200804026B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2193196B1 (en) 2007-09-28 2016-07-13 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
LT3604510T (lt) 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
MX343784B (es) 2010-10-06 2016-11-23 Medimmune Ltd Factor ii y fibrinogeno para tratamiento de trastornos hemostaticos.
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
SG11201500579SA (en) 2012-07-25 2015-02-27 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
KR20150103205A (ko) 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
SG11201601221XA (en) * 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
CA2928762A1 (en) * 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
CA2937418A1 (en) * 2014-01-24 2015-07-30 Pfizer Inc. Compositions and methods for treating intracerebral hemorrhage
MX378899B (es) 2014-05-26 2025-03-10 Academisch Ziekenhuis Leiden Proteinas prohemostaticas para el tratamiento de hemorragias.
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
CA3034566A1 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US20250066436A1 (en) 2021-12-22 2025-02-27 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0708658A4 (en) 1993-04-16 1997-05-21 Wistar Inst RECOMBINANT CYTOMEGALOVIRUS VACCINE
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
WO1996026742A1 (en) 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
US20040102388A1 (en) * 2000-03-22 2004-05-27 High Katherine A. Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
ES2629099T3 (es) * 2008-12-19 2017-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Derivados de serin proteasa y usos en la prevención o el tratamiento de y trastornos de la coagulación sanguinea

Also Published As

Publication number Publication date
EP2431390A1 (en) 2012-03-21
HK1165444A1 (en) 2012-10-05
NZ568108A (en) 2011-09-30
AU2006315175B2 (en) 2013-02-07
JP6571735B2 (ja) 2019-09-04
CA2971971A1 (en) 2007-05-24
ECSP088452A (es) 2008-07-30
MX2008006313A (es) 2008-11-06
RU2570547C2 (ru) 2015-12-10
NO345177B1 (no) 2020-10-26
SI1948690T1 (sl) 2014-09-30
CA2629491C (en) 2019-05-07
MX336958B (es) 2016-02-05
US20160362673A1 (en) 2016-12-15
US9896676B2 (en) 2018-02-20
JP2018033459A (ja) 2018-03-08
IL191310A (en) 2015-06-30
EP1948690A2 (en) 2008-07-30
RU2008123398A (ru) 2009-12-27
BRPI0618654B1 (pt) 2021-10-19
NO20200670A1 (no) 2008-07-30
CN101356192B (zh) 2013-09-11
US8383386B2 (en) 2013-02-26
KR20160029135A (ko) 2016-03-14
PL1948690T3 (pl) 2014-11-28
RU2011130932A (ru) 2013-01-27
CR9956A (es) 2008-08-21
NO20200671A1 (no) 2008-07-30
WO2007059513A3 (en) 2007-11-29
KR101827569B1 (ko) 2018-02-09
CA2629491A1 (en) 2007-05-24
US20140120155A1 (en) 2014-05-01
PT1948690E (pt) 2014-09-08
EP2431389A1 (en) 2012-03-21
EP2423224B1 (en) 2015-08-12
SV2008002906A (es) 2008-10-22
EP1948690B1 (en) 2014-06-11
JP2016005464A (ja) 2016-01-14
KR20140005383A (ko) 2014-01-14
ES2496567T3 (es) 2014-09-19
KR20140115374A (ko) 2014-09-30
ZA200804026B (en) 2009-10-28
EP2423224A1 (en) 2012-02-29
NO20082182L (no) 2008-07-30
HK1128699A1 (en) 2009-11-06
ES2549929T3 (es) 2015-11-03
EP1948690A4 (en) 2009-06-17
BRPI0618654A2 (pt) 2011-09-06
CN101356192A (zh) 2009-01-28
US20180251745A1 (en) 2018-09-06
GT200800065A (es) 2008-11-03
DK1948690T3 (da) 2014-09-01
MY162181A (en) 2017-05-31
JP5957167B2 (ja) 2016-07-27
AU2006315175A1 (en) 2007-05-24
JP2009515559A (ja) 2009-04-16
WO2007059513A2 (en) 2007-05-24
KR101574042B1 (ko) 2015-12-03
BRPI0618654A8 (pt) 2019-01-15
JP6236194B2 (ja) 2017-11-22
KR20080078664A (ko) 2008-08-27
JP5823088B2 (ja) 2015-11-25
KR101600158B1 (ko) 2016-03-08
US20090175931A1 (en) 2009-07-09
EP2431390B1 (en) 2015-08-12
US9410137B2 (en) 2016-08-09
JP2014073127A (ja) 2014-04-24

Similar Documents

Publication Publication Date Title
CR9956A (es) Metodos y composiciones para modular la hemostasia
CR10213A (es) Moduladores de la proteína quinasa aurora
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
NO20092637L (no) Fremgangsmater for behandling
CY1117833T1 (el) Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου
NO20071127L (no) Triazoloftalaziner
DE602008000754D1 (de) Tropanverbindungen
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
PL2963031T3 (pl) Proleki tetrahydrokannabinolu, kompozycje zawierające proleki tetrahydrokannabinolu i sposoby ich stosowania
EA200802008A1 (ru) Фармацевтические композиции
SV2009003434A (es) Inhibicion de arni de expresion de alfa-enac
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
EA201100037A1 (ru) Органические соединения
CY2014012I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
ECSP088558A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
BRPI0813000A2 (pt) Composições terapêuticas e uso das mesmas
PL2214656T3 (pl) Kompozycje i sposoby wzmacniania odpowiedzi immunologicznej
BRPI0720211A2 (pt) Derivado de indanona, composição, e, uso de uma composição
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
DE602005007237D1 (de) Haarpflegezusammensetzungen
EA200870515A1 (ru) Моноциклические гетероарильные соединения
ATE544759T1 (de) 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
EP1951050A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD